Skip to main content
Fig. 2 | BMC Nephrology

Fig. 2

From: Disease characteristics and outcomes in patients with chronic kidney disease and type 2 diabetes: a matched cohort study of spironolactone users and non-users

Fig. 2

Clinical events of interest in the post-inclusion period in matched spironolactone users and non-users. A 60-day gap was used to count acute events (ACS, acute kidney injury, stroke [any], HF, and hyperkalaemia), and a 360-day gap was used to count chronic events (PAD and diabetic retinopathy). ACS, acute coronary syndrome; HF, heart failure; PAD, peripheral artery disease

Back to article page